Patents by Inventor Fredrik Lehmann
Fredrik Lehmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11896668Abstract: The present invention is directed to novel lyophilized pharmaceutical preparations comprising a cytotoxic dipeptides such as melphalan flufenamide and one or more excipient(s) selected from the group comprising a polysorbate; a polyethylene glycol; ?-cyclodextrin; ocyclodextrin; hydroxypropyl-?-cyclodextrin; sulfobutylether-?-cyclodextrin; lactose; benzyl alcohol; disodium succinate; propylene glycol; Cremophor EL; Dimethyl sulfoxide; D-mannitol; Trehalose; Sucrose and an amino acid. This preparation may be further formulated and is useful in cancer therapy.Type: GrantFiled: April 27, 2022Date of Patent: February 13, 2024Assignee: Oncopeptides ABInventors: Jack Spira, Fredrik Lehmann
-
Publication number: 20220323585Abstract: The present invention is directed to novel lyophilized pharmaceutical preparations comprising a cytotoxic dipeptides such as melphalan flufenamide and one or more excipient(s) selected from the group comprising a polysorbate; a polyethylene glycol; ?-cyclodextrin; ocyclodextrin; hydroxypropyl-?-cyclodextrin; sulfobutylether-?-cyclodextrin; lactose; benzyl alcohol; disodium succinate; propylene glycol; Cremophor EL; Dimethyl sulfoxide; D-mannitol; Trehalose; Sucrose and an amino acid. This preparation may be further formulated and is useful in cancer therapy.Type: ApplicationFiled: April 27, 2022Publication date: October 13, 2022Applicant: ONCOPEPTIDES ABInventors: Jack SPIRA, Fredrik LEHMANN
-
Publication number: 20220184021Abstract: The invention provides a pharmaceutical formulation comprising (or consisting essentially of) the following components: i) melflufen, or a salt thereof; ii) propylene glycol; iii) optionally one or more physiologically acceptable aqueous solvent(s); and iv) optionally one or more additional therapeutic agent(s); or a pharmaceutical formulation comprising (or consisting essentially of) the following components: i) melflufen, or a salt thereof; ii) polyethylene glycol; iii) optionally one or more physiologically acceptable aqueous solvent(s); and iv) optionally one or more additional therapeutic agent(s). The invention also provides methods for preparing the pharmaceutical formulations of the invention, kits and uses of the pharmaceutical formulations of the invention.Type: ApplicationFiled: April 17, 2020Publication date: June 16, 2022Applicant: Oncopeptides ABInventors: Fredrik Lehmann, Peter Teodorovic
-
Patent number: 11344622Abstract: The present invention is directed to novel lyophilized pharmaceutical preparations comprising a cytotoxic dipeptides such as melphalan flufenamide and one or more excipient(s) selected from the group comprising a polysorbate; a polyethylene glycol; ?-cyclodextrin; ocyclodextrin; hydroxypropyl-?-cyclodextrin; sulfobutylether-?-cyclodextrin; lactose; benzyl alcohol; disodium succinate; propylene glycol; Cremophor EL; Dimethyl sulfoxide; D-mannitol; Trehalose; Sucrose and an amino acid. This preparation may be further formulated and is useful in cancer therapy.Type: GrantFiled: July 22, 2020Date of Patent: May 31, 2022Assignee: ONCOPEPTIDES ABInventors: Jack Spira, Fredrik Lehmann
-
Publication number: 20220106349Abstract: The invention provides novel compounds that are derivatives of Azithromycin and that have been found by the current inventors to have low antimicrobial activity but significant epithelial barrier enhancement properties. The invention further provides use of the compounds as a medicament, in particular in the treatment or prophylaxis of a disease or condition that is caused by a defect in epithelial cells or tissue, or a disease or condition that benefits from enhancement or restoration of epithelial barrier function, for example diseases of the respiratory tract.Type: ApplicationFiled: December 15, 2021Publication date: April 7, 2022Applicant: EpiEndo Pharmaceuticals ehfInventors: Fridrik Runar Gardarsson, Fredrik Lehmann, Peter Teodorovic
-
Patent number: 11236120Abstract: The invention provides novel compounds that are derivatives of Azithromycin and that have been found by the current inventors to have low antimicrobial activity but significant epithelial barrier enhancement properties. The invention further provides use of the compounds as a medicament, in particular in the treatment or prophylaxis of a disease or condition that is caused by a defect in epithelial cells or tissue, or a disease or condition that benefits from enhancement or restoration of epithelial barrier function, for example diseases of the respiratory tract.Type: GrantFiled: June 18, 2020Date of Patent: February 1, 2022Assignee: EPIENDO PHARMACEUTICALS EHFInventors: Fridrik Runar Gardarsson, Fredrik Lehmann, Peter Teodorovic
-
Publication number: 20210388024Abstract: The invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof (Formula I), wherein, each R1—R30 is independently selected from the group consisting of H and deuterium, and at least one of R1—R30 is deuterium with an abundance level greater than the naturally occurring abundance of deuterium. The invention also provides pharmaceutical compositions containing the compounds, and uses of the compounds.Type: ApplicationFiled: October 17, 2019Publication date: December 16, 2021Applicant: Oncopeptides ABInventor: Fredrik Lehmann
-
Patent number: 10869928Abstract: The present invention is directed to novel lyophilized pharmaceutical preparations comprising a cytotoxic dipeptides such as melphalan flufenamide and one or more excipient(s) selected from the group comprising a polysorbate; a polyethylene glycol; ?-cyclodextrin; ocyclodextrin; hydroxypropyl-?-cyclodextrin; sulfobutylether-?-cyclodextrin; lactose; benzyl alcohol; disodium succinate; propylene glycol; Cremophor EL; Dimethyl sulfoxide; D-mannitol; Trehalose; Sucrose and an amino acid. This preparation may be further formulated and is useful in cancer therapy.Type: GrantFiled: December 19, 2019Date of Patent: December 22, 2020Assignee: ONCOPEPTIDES ABInventors: Jack Spira, Fredrik Lehmann
-
Publication number: 20200345848Abstract: The present invention is directed to novel lyophilized pharmaceutical preparations comprising a cytotoxic dipeptides such as melphalan flufenamide and one or more excipient(s) selected from the group comprising a polysorbate; a polyethylene glycol; ?-cyclodextrin; ocyclodextrin; hydroxypropyl-?-cyclodextrin; sulfobutylether-?-cyclodextrin; lactose; benzyl alcohol; diso dium succinate; propylene glycol; Cremophor EL; Dimethyl sulfoxide; D-mannitol; Trehalose; Sucrose and an amino acid. This preparation may be further formulated and is useful in cancer therapy.Type: ApplicationFiled: July 22, 2020Publication date: November 5, 2020Applicant: ONCOPEPTIDES ABInventors: Jack SPIRA, Fredrik LEHMANN
-
Publication number: 20200317710Abstract: The invention provides novel compounds that are derivatives of Azithromycin and that have been found by the current inventors to have low antimicrobial activity but significant epithelial barrier enhancement properties. The invention further provides use of the compounds as a medicament, in particular in the treatment or prophylaxis of a disease or condition that is caused by a defect in epithelial cells or tissue, or a disease or condition that benefits from enhancement or restoration of epithelial barrier function, for example diseases of the respiratory tract.Type: ApplicationFiled: June 18, 2020Publication date: October 8, 2020Applicant: EpiEndo Pharmaceuticals ehfInventors: Fridrik Runar Gardarsson, Fredrik Lehmann, Peter Teodorovic
-
Patent number: 10723752Abstract: The invention provides novel compounds that are derivatives of Azithromycin and that have been found by the current inventors to have low antimicrobial activity but significant epithelial barrier enhancement properties. The invention further provides use of the compounds as a medicament, in particular in the treatment or prophylaxis of a disease or condition that is caused by a defect in epithelial cells or tissue, or a disease or condition that benefits from enhancement or restoration of epithelial barrier function, for example diseases of the respiratory tract.Type: GrantFiled: November 21, 2016Date of Patent: July 28, 2020Assignee: EPIENDO PHARMACEUTICALS EHFInventors: Fridrik Runar Gardarsson, Fredrik Lehmann, Peter Teodorovic
-
Publication number: 20200121794Abstract: The present invention is directed to novel lyophilized pharmaceutical preparations comprising a cytotoxic dipeptides such as melphalan flufenamide and one or more excipient(s) selected from the group comprising a polysorbate; a polyethylene glycol; ?-cyclodextrin; ocyclodextrin; hydroxypropyl-?-cyclodextrin; sulfobutylether-?-cyclodextrin; lactose; benzyl alcohol; disodium succinate; propylene glycol; Cremophor EL; Dimethyl sulfoxide; D-mannitol; Trehalose; Sucrose and an amino acid. This preparation may be further formulated and is useful in cancer therapy.Type: ApplicationFiled: December 19, 2019Publication date: April 23, 2020Applicant: ONCOPEPTIDES ABInventors: Jack SPIRA, Fredrik LEHMANN
-
Patent number: 10543274Abstract: The present invention is directed to novel lyophilized pharmaceutical preparations comprising a cytotoxic dipeptides such as melphalan flufenamide and one or more excipient(s) selected from the group comprising a polysorbate; a polyethylene glycol; ?-cyclodextrin; ocyclodextrin; hydroxypropyl-?-cyclodextrin; sulfobutylether-?-cyclodextrin; lactose; benzyl alcohol; disodium succinate; propylene glycol; Cremophor EL; Dimethyl sulfoxide; D-mannitol; Trehalose; Sucrose and an amino acid. This preparation may be further formulated and is useful in cancer therapy.Type: GrantFiled: April 12, 2019Date of Patent: January 28, 2020Assignee: ONCOPEPTIDES ABInventors: Jack Spira, Fredrik Lehmann
-
Publication number: 20200009252Abstract: The present invention is directed to novel lyophilized pharmaceutical preparations comprising a cytotoxic dipeptides such as melphalan flufenamide and one or more excipient(s) selected from the group comprising a polysorbate; a polyethylene glycol; ?-cyclodextrin; ocyclodextrin; hydroxypropyl-?-cyclodextrin; sulfobutylether-?-cyclodextrin; lactose; benzyl alcohol; disodium succinate; propylene glycol; Cremophor EL; Dimethyl sulfoxide; D-mannitol; Trehalose; Sucrose and an amino acid. This preparation may be further formulated and is useful in cancer therapy.Type: ApplicationFiled: June 28, 2019Publication date: January 9, 2020Applicant: ONCOPEPTIDES ABInventors: Jack SPIRA, Fredrik LEHMANN
-
Publication number: 20190240332Abstract: The present invention is directed to novel lyophilized pharmaceutical preparations comprising a cytotoxic dipeptides such as melphalan flufenamide and one or more excipient(s) selected from the group comprising a polysorbate; a polyethylene glycol; ?-cyclodextrin; ocyclodextrin; hydroxypropyl-?-cyclodextrin; sulfobutylether-?-cyclodextrin; lactose; benzyl alcohol; disodium succinate; propylene glycol; Cremophor EL; Dimethyl sulfoxide; D-mannitol; Trehalose; Sucrose and an amino acid. This preparation may be further formulated and is useful in cancer therapy.Type: ApplicationFiled: April 12, 2019Publication date: August 8, 2019Applicant: ONCOPEPTIDES ABInventors: Jack SPIRA, Fredrik LEHMANN
-
Patent number: 10322182Abstract: The present invention is directed to novel lyophilized pharmaceutical preparations comprising a cytotoxic dipeptides such as melphalan flufenamide and one or more excipient(s) selected from the group comprising a polysorbate; a polyethylene glycol; ?-cyclodextrin; ocyclodextrin; hydroxypropyl-?-cyclodextrin; sulfobutylether-?-cyclodextrin; lactose; benzyl alcohol; disodium succinate; propylene glycol; Cremophor EL; Dimethyl sulfoxide; D-mannitol; Trehalose; Sucrose and an amino acid. This preparation may be further formulated and is useful in cancer therapy.Type: GrantFiled: August 1, 2016Date of Patent: June 18, 2019Assignee: ONCOPEPTIDES ABInventors: Jack Spira, Fredrik Lehmann
-
Patent number: 10285947Abstract: The present invention is directed to lyophilized pharmaceutical preparations comprising melphalan flufenamide, or pharmaceutically acceptable salts thereof, methods for their preparation, compositions comprising the lyophilized pharmaceutical preparations and their use in the treatment of cancer.Type: GrantFiled: May 9, 2016Date of Patent: May 14, 2019Assignee: Oncopeptides ABInventors: Jack Spira, Fredrik Lehmann
-
Patent number: 10285946Abstract: The present invention is directed to lyophilized pharmaceutical preparations comprising melphalan flufenamide, or pharmaceutically acceptable salts thereof, and sucrose. Further independent claims are directed to methods for their preparation, compositions comprising the lyophilized pharmaceutical preparations and their use in the treatment of cancer.Type: GrantFiled: October 24, 2013Date of Patent: May 14, 2019Assignee: Oncopeptides ABInventors: Jack Spira, Fredrik Lehmann
-
Publication number: 20180354981Abstract: The invention provides novel compounds that are derivatives of Azithromycin and that have been found by the current inventors to have low antimicrobial activity but significant epithelial barrier enhancement properties. The invention further provides use of the compounds as a medicament, in particular in the treatment or prophylaxis of a disease or condition that is caused by a defect in epithelial cells or tissue, or a disease or condition that benefits from enhancement or restoration of epithelial barrier function, for example diseases of the respiratory tract.Type: ApplicationFiled: November 21, 2016Publication date: December 13, 2018Applicant: EPI-ENDO Pharmaceuticals ehfInventors: Fridrik Runar Gardarsson, Fredrik Lehmann, Peter Teodorovic
-
Publication number: 20170049894Abstract: The present invention is directed to novel lyophilized pharmaceutical preparations comprising a cytotoxic dipeptides such as melphalan flufenamide and one or more excipient(s) selected from the group comprising a polysorbate; a polyethylene glycol; ?-cyclodextrin; ocyclodextrin; hydroxypropyl-?-cyclodextrin; sulfobutylether-?-cyclodextrin; lactose; benzyl alcohol; disodium succinate; propylene glycol; Cremophor EL; Dimethyl sulfoxide; D-mannitol; Trehalose; Sucrose and an amino acid. This preparation may be further formulated and is useful in cancer therapy.Type: ApplicationFiled: August 1, 2016Publication date: February 23, 2017Applicant: ONCOPEPTIDES ABInventors: Jack SPIRA, Fredrik LEHMANN